
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
CDISC and HL7 Joint Worldwide Clinical Research Standards Educational Events Planned for 2008






